Flynn et al.: does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?

By Omura G.A.  

Gynecologic Oncology, Vol. 90, Iss. 2, 2003-08 ,pp. : 498-498

Elsevier

Access to resources Recommend Favorite

Does the Interval from Primary Surgery to Chemotherapy Influence Progression-Free Survival in Ovarian Cancer?

By Flynn P.M.   Paul J.   Cruickshank D.J.  

Gynecologic Oncology, Vol. 86, Iss. 3, 2002-09 ,pp. : 354-357

Academic Press

Access to resources Recommend Favorite

Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

By Tas Faruk   Karabulut Senem   Serilmez Murat   Ciftci Rumeysa   Duranyildiz Derya  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 631-637

Springer Publishing Company

Access to resources Recommend Favorite

Elevated nm23 Protein Expression Is Correlated with Diminished Progression-Free Survival in Patients with Epithelial Ovarian Carcinoma

By Srivatsa P.J.   Cliby W.A.   Keeney G.L.   Dodson M.K.   Suman V.J.   Roche P.C.   Podratz K.C.  

Gynecologic Oncology, Vol. 60, Iss. 3, 1996-03 ,pp. : 363-372

Academic Press

Access to resources Recommend Favorite

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer

By Fredstorp-Lidebring M.   Bendahl P.-O.   Brunner N.   Casslen B.   Hogberg T.   Langstrom-Einarsson E.   Willen R.   Ferno M.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2339-2348

Elsevier

Access to resources Recommend Favorite